Research Library › Incretin & Amylin
Tirzepatide is a synthetic 39-amino-acid peptide with a C20 fatty diacid side chain, designed as a single molecule that activates both the GIP and GLP-1 receptors. It was discovered at Eli Lilly under the code LY3298176, described in a 2018 discovery paper, and first approved by the FDA in May 2022 as Mounjaro for type 2 diabetes. As of October 2026 it is FDA-approved only in Lilly’s Mounjaro and Zepbound, and unapproved or “research use” versions have drawn FDA warning letters.
Key facts
| Type | Synthetic 39-amino-acid peptide with a C20 fatty diacid moiety |
|---|---|
| Other names | LY3298176; brands Mounjaro and Zepbound |
| Developed by | Eli Lilly and Company, Indianapolis, USA |
| First described | 2018, discovery-to-proof-of-concept paper in Molecular Metabolism |
| Designed target | Dual agonist of the GIP receptor and the GLP-1 receptor |
| Regulatory status (Oct 2026) | FDA-approved as Mounjaro (2022) and Zepbound (2023); shortage resolved Dec 2024; FDA proposed in April 2026 to exclude it from the 503B bulks list; unapproved versions subject to FDA warnings |
Who developed it
Tirzepatide was discovered and developed by Eli Lilly and Company. A team of Lilly scientists led the work that took the molecule, then coded LY3298176, from discovery to early clinical testing, and published the program in Molecular Metabolism in 2018 [1].
Lilly is the sponsor of both FDA-approved tirzepatide products, Mounjaro and Zepbound [2, 3].
Structure and design
Tirzepatide is a 39-amino-acid peptide joined to a C20 fatty diacid moiety. Regulators describe that side chain as enabling binding to albumin, which was intended to lengthen the molecule’s half-life [4].
Its design reflects a research question rather than a simple copy of one hormone. Lilly’s scientists set out to build a single peptide able to act at the receptors for two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and GLP-1, in order to study whether adding GIP receptor activity changes what is seen with selective GLP-1 receptor agonists [1]. The FDA classed Mounjaro as a novel drug, the first of this dual-receptor kind [2].
Research history
- 2018: Lilly publishes the discovery and early clinical work on LY3298176 [1]
- 13 May 2022: FDA approves Mounjaro for type 2 diabetes [2]
- December 2022: Australia’s TGA registers Mounjaro [4]
- 8 November 2023: FDA approves Zepbound for chronic weight management [3]
- 20 December 2024: FDA approves Zepbound for an indication related to obstructive sleep apnea in adults with obesity [5]
Regulatory status as of October 2026
Tirzepatide is FDA-approved only as the active ingredient of Lilly’s Mounjaro and Zepbound. Tirzepatide injection was on the FDA drug shortage list for a period. The FDA declared the shortage resolved, first in October 2024 and again, after litigation, on 19 December 2024. Its temporary enforcement flexibility for compounders ended in March 2025 [6].
On 30 April 2026 the FDA proposed excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list for outsourcing facilities, citing no demonstrated clinical need. Comments closed on 29 June 2026 [7]; no final determination had been announced as of October 2026.
The FDA states that compounded and other unapproved tirzepatide products are not reviewed for safety, effectiveness or quality, and that it has warned firms selling tirzepatide labeled “for research purposes” or “not for human consumption” [8]. In one March 2026 warning letter, the agency said a “Research Use Only” label did not change its conclusion that tirzepatide and retatrutide sold online were unapproved new drugs [9]. In March 2026 it also warned 30 telehealth companies about marketing claims for compounded GLP-1 products [10].
About this reference page
Kalibra Labs does not currently supply Tirzepatide. This page is published as a neutral scientific and regulatory reference. Browse the Incretin & Amylin guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Who makes tirzepatide?
Tirzepatide was discovered and developed by Eli Lilly and Company, which markets it as Mounjaro and Zepbound [1, 2, 3].
When was tirzepatide approved?
The FDA approved tirzepatide on 13 May 2022 as Mounjaro for type 2 diabetes, and on 8 November 2023 as Zepbound for chronic weight management [2, 3].
Is tirzepatide a peptide?
Yes. Tirzepatide is a synthetic 39-amino-acid peptide joined to a C20 fatty diacid moiety, which regulators describe as enabling binding to albumin [4].
Are "research use only" tirzepatide products legal?
The FDA has stated that a “Research Use Only” label does not stop such products from being regulated as unapproved new drugs when evidence shows they are intended for people [9].
Sources
- Coskun T, Sloop KW, Loghin C, et al., Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009. Link
- U.S. FDA. Novel Drug Approvals for 2022 (Mounjaro, approved 13 May 2022). Link
- U.S. FDA. FDA approves new medication for chronic weight management. Press announcement, 8 Nov 2023. Link
- Therapeutic Goods Administration (Australia). Australian Product Information / AusPMD: Mounjaro (tirzepatide), registration decision 22 Dec 2022. Link
- U.S. FDA. FDA approves first medication for obstructive sleep apnea. Press announcement, 20 Dec 2024. Link
- U.S. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated through 1 Apr 2026). Link
- U.S. FDA. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. Press announcement, 30 Apr 2026. Link
- U.S. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated 1 Oct 2026). Link
- U.S. FDA. Warning letter to Gram Peptides, MARCS-CMS 721806, 31 Mar 2026. Link
- U.S. FDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. Press announcement, 3 Mar 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
